Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.26
+0.570033.73%
Post-market: 2.22-0.0400-1.77%19:59 EDT
Volume:13.25M
Turnover:28.51M
Market Cap:533.36M
PE:-9.89
High:2.29
Open:1.77
Low:1.76
Close:1.69
Loading ...

Company Profile

Company Name:
Akebia Therapeutics
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
167
Office Location:
245 First Street,Suite 1400,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
617 871 2099
Introduction:
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
John P. Butler
Director, President and Chief Executive Officer
Muneer A. Satter
Director (Chairperson)
Duane Nash
Director
Maxine Gowen
Director
Michael D. Clayman
Director
Michael S. Wyzga
Director
Ronald C. Renaud, Jr.
Director
Scott A. Canute
Director

Shareholders

Name
Position
John P. Butler
Director, President and Chief Executive Officer
Bradley J. Maroni
Senior Vice President and Chief Medical Officer
Jason A. Amello
Senior Vice President, Chief Financial Officer and Treasurer
Karen Tubridy
Senior Vice President, Chief Development Officer
Michel Dahan
Senior Vice President and Chief Business Officer
Nicole R. Hadas
Senior Vice President, General Counsel and Secretary